Evidence map›Paper›PMID 37834379›Full record

ArticleInternational journal of molecular sciences2023

Transcriptional Dysregulation and Impaired Neuronal Activity in

Gilles Maussion, Cecilia Rocha, Narges Abdian, Dimitri Yang, Julien Turk, Dulce Carrillo Valenzuela, Luisa Pimentel, Zhipeng You, Barbara Morquette, Michael Nicouleau and 12 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 3 institutions in 2 countries.

Gilles MaussionThe Neuro's Early Drug Discovery Unit (EDDU), McGill University, Montreal, QC H3A 2B4, Canada.ORCID 0000-0001-5785-6238
Cecilia RochaThe Neuro's Early Drug Discovery Unit (EDDU), McGill University, Montreal, QC H3A 2B4, Canada.
Narges AbdianThe Neuro's Early Drug Discovery Unit (EDDU), McGill University, Montreal, QC H3A 2B4, Canada.
Dimitri YangThe Neuro's Early Drug Discovery Unit (EDDU), McGill University, Montreal, QC H3A 2B4, Canada.
Julien TurkThe Neuro's Early Drug Discovery Unit (EDDU), McGill University, Montreal, QC H3A 2B4, Canada.
Dulce Carrillo ValenzuelaThe Neuro's Early Drug Discovery Unit (EDDU), McGill University, Montreal, QC H3A 2B4, Canada.
Luisa PimentelThe Neuro's Early Drug Discovery Unit (EDDU), McGill University, Montreal, QC H3A 2B4, Canada.ORCID 0000-0001-6936-0280
Zhipeng YouThe Neuro's Early Drug Discovery Unit (EDDU), McGill University, Montreal, QC H3A 2B4, Canada.
Barbara MorquetteThe Neuro's Early Drug Discovery Unit (EDDU), McGill University, Montreal, QC H3A 2B4, Canada.
Michael NicouleauThe Neuro's Early Drug Discovery Unit (EDDU), McGill University, Montreal, QC H3A 2B4, Canada.
Eric DeneaultRegulatory Research Division, Centre for Oncology, Radiopharmaceuticals and Research, Biologic and Radiopharmaceutical Drugs Directorate, Health Products and Food Branch, Health Canada, Ottawa, ON K1A 0K9, Canada.ORCID 0000-0002-6875-0380
Samuel HigginsRoche Sequencing, Computational Science and Informatics, Roche Molecular Systems, Santa Clara, CA 95050, USA.
Carol X-Q ChenThe Neuro's Early Drug Discovery Unit (EDDU), McGill University, Montreal, QC H3A 2B4, Canada.
Wolfgang E ReintschThe Neuro's Early Drug Discovery Unit (EDDU), McGill University, Montreal, QC H3A 2B4, Canada.
Stanley HoResearch and Early Development, Roche Molecular Systems, Pleasanton, CA 94588, USA.ORCID 0009-0007-5892-2808
Vincent SoubannierThe Neuro's Early Drug Discovery Unit (EDDU), McGill University, Montreal, QC H3A 2B4, Canada.ORCID 0000-0002-0347-1364
Sarah LépineThe Neuro's Early Drug Discovery Unit (EDDU), McGill University, Montreal, QC H3A 2B4, Canada.
Zora ModrusanGenentech, South San Francisco, CA 94080, USA.
Jessica LundGenentech, South San Francisco, CA 94080, USA.
William StephensonGenentech, South San Francisco, CA 94080, USA.ORCID 0000-0002-3779-417X
Rajib SchubertResearch and Early Development, Roche Molecular Systems, Pleasanton, CA 94588, USA.
Thomas M DurcanThe Neuro's Early Drug Discovery Unit (EDDU), McGill University, Montreal, QC H3A 2B4, Canada.ORCID 0000-0003-3942-1956
Montreal Neurological Institute and Hospital · CAHealth Canada · CALa Roche College · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fragile X syndrome (FXS) is caused by a repression of the

Indexed as

Fragile X SyndromeInduced Pluripotent Stem CellsAnimalsFragile X Messenger Ribonucleoprotein 1HumansMiceMice, KnockoutNeurogenesisNeuronsRNA, MessengerFMR1 protein, humanFragile X Messenger Ribonucleoprotein 1RNA, Messengeractivity-dependent developmentcortical neuronsFragile X syndromeiPSC-derived neuronsmultielectrode arrayRNA transcriptomicssynapses

Identifiers

PMID37834379
PMCPMC10573568
OpenAlexW4387405672

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.